All forward-looking statements reflect the company's expectations only as of the date of this release and should not be relied upon as reflecting the company's views, expectations or beliefs at any date subsequent to the date of this release. Idenix anticipates that subsequent events and developments may cause these views, expectations and beliefs to change. However, while Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.
IDENIX PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (IN THOUSANDS, EXCEPT PER SHARE DATA) (UNAUDITED) Three Months Ended Years Ended December 31, December 31, 2008 2007 2008 2007 Revenues: Collaboration revenue - related party $4,247 $12,573 $9,815 $64,751 Other revenue 21 29 234 3,277 Total revenues 4,268 12,602 10,049 68,028 Operating expenses (1): Cost of sales 479 1,487 1,745 2,001 Research and development 11,949 20,294 53,887 85,839 Selling, general and administrative 5,702 9,278 27,130 63,348 Restructuring and
|SOURCE Idenix Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved